- Apr 15
- 12 min read
Updated: May 13
A guide for patients and families weighing treatment options abroad
Introduction
There are treatments that shift what medicine can do for a specific group of patients. CAR-T cell therapy is one of them.
For people with certain blood cancers who have not responded to — or have relapsed after — chemotherapy, stem cell transplantation, or targeted therapies, CAR-T cancer treatment has produced outcomes that were not reliably achievable before. Complete remissions in patients with no remaining standard options. Durable responses in diseases where median survival was previously measured in months.
The obstacle is access. In the United States, a single CAR-T infusion costs upward of $450,000 before hospital and supportive care fees are added. And for patients in Indonesia, Vietnam, Thailand, the Philippines, or Malaysia, the financial and logistical distance has historically put this treatment out of reach.
That situation has changed meaningfully over the past few years. This article covers the current state of CAR-T cancer treatment globally — which countries have the clinical infrastructure to deliver it, what patients realistically pay in each, and why China in particular has become a credible option for Southeast Asian patients who cannot access treatment at home.
What Is CAR-T Cancer Treatment?
CAR-T stands for Chimeric Antigen Receptor T-cell therapy. It is a form of immunotherapy that uses a patient's own immune cells — genetically modified in a laboratory — to target and kill cancer cells.
The process has four stages:
Collection: T-cells (a type of white blood cell) are withdrawn from the patient's blood through a procedure called leukapheresis.
Engineering: In a laboratory, these T-cells are genetically modified to carry chimeric antigen receptors (CARs) on their surface — proteins that bind to a specific marker on cancer cells.
Expansion: The modified cells are grown in large quantities, typically hundreds of millions, before being prepared for infusion.
Infusion: The cells are returned to the patient, where they locate and destroy cancer cells that carry the target marker.
Because each batch is made from a specific patient's own cells, CAR-T cannot be mass-produced like a conventional drug. This is the primary driver of its cost and the logistical complexity involved in delivering it.
CAR-T therapy has shown clinically significant results in:
B-cell acute lymphoblastic leukemia (B-ALL), particularly in children and young adults
Diffuse large B-cell lymphoma (DLBCL)
Multiple myeloma
Follicular lymphoma
Mantle cell lymphoma
Since 2023, clinical trials have also been testing CAR-T in solid tumors — including lung, liver, gastric, and nasopharyngeal cancers — with early data that is drawing clinical interest in Asia, where some of these cancers are more common.
Why Access Has Been Limited — and What Has Changed
Manufacturing CAR-T requires biosafety-certified laboratory facilities, specialized cell-processing equipment, cold-chain logistics, and close coordination between the treating hospital and the manufacturing site. For years, this infrastructure existed only in a small number of high-income countries.
Between 2020 and 2025, the number of countries with nationally approved CAR-T products more than tripled. China approved three domestic products and built one of the world's largest cell therapy manufacturing sectors. India approved its first homegrown CAR-T product in 2023.
For patients in Southeast Asia, these developments have practical consequences. Treatment that was previously accessible only in the United States or Europe, at costs beyond reach for most families, is now available at clinical centers in countries that are geographically and financially closer.
The Best Countries for CAR-T Cancer Treatment in 2026
1. 🇺🇸 United States
The United States has the largest number of nationally approved CAR-T products. As of early 2026, the FDA has approved seven, including:
Kymriah (tisagenlecleucel) — for B-ALL and DLBCL
Yescarta (axicabtagene ciloleucel) — for large B-cell lymphoma and follicular lymphoma
Carvykti (ciltacabtagene autoleucel) — for multiple myeloma
Breyanzi (lisocabtagene maraleucel) — for B-cell lymphoma
Leading programs operate at MD Anderson Cancer Center, Memorial Sloan Kettering, and the Mayo Clinic, all of which have dedicated CAR-T units with structured post-infusion monitoring protocols and high case volumes.
Drug costs (approximate, USD):
Kymriah: ~$475,000
Yescarta: ~$373,000
Carvykti: ~$465,000
Hospital fees, pre-conditioning chemotherapy, inpatient stay, and monitoring add approximately $100,000–$300,000 on top of the drug cost.
Total cost for an international patient without US insurance: $500,000–$800,000 USD
For most Southeast Asian patients, this range is not financially viable. Visa processing, extended stays averaging 10–14 weeks, and the absence of local family support add further difficulty.
2. 🇨🇳 China
China's CAR-T program deserves detailed coverage here because it is both clinically substantive and substantially more affordable than any Western country's equivalent — a combination that is directly relevant to Southeast Asian patients considering treatment abroad.
What China Has Approved
By 2025, China's National Medical Products Administration (NMPA) had approved three CAR-T products:
Relma-cel (relmacabtagene autoleucel) by JW Therapeutics — for relapsed or refractory large B-cell lymphoma
Yescarta (axicabtagene ciloleucel) — co-manufactured in China by Fosun Kite, for large B-cell lymphoma
Equecabtagene autoleucel (CT053) by CARsgen Therapeutics — for relapsed or refractory multiple myeloma
These are not investigational products. Each has gone through NMPA review based on clinical safety and efficacy data. The NMPA operates a conditional approval pathway for oncology products — similar in structure to the FDA's Accelerated Approval and the EMA's Conditional Marketing Authorization — that allows promising therapies to reach patients with serious conditions while post-market data collection continues.
China's Clinical Trial Volume
Beyond approved products, China currently runs more active CAR-T clinical trials than any other country. A 2024 analysis in Nature Medicine reported that China accounts for over 40% of all active CAR-T trials globally. A significant proportion of these trials are investigating CAR-T in solid tumors — gastric, liver, lung, and nasopharyngeal cancers — where Western programs remain at early stages.
For patients whose cancer type is not covered by an approved product, trial enrollment at a Chinese center may be a clinically sound alternative. Trial costs are often partially or fully covered by the sponsoring institution.
Why China Has Developed This Capacity
Government policy. China's 14th Five-Year Plan (2021–2025) identified cell therapy as a strategic biomedical sector, directing research funding toward it and streamlining regulatory review for oncology products.
Patient volume. China diagnoses approximately 4.8 million new cancer cases per year — the highest absolute number of any country. This allows Chinese clinical trial programs to recruit patients at a pace that would take Western centers far longer, producing larger datasets in shorter timeframes.
Domestic manufacturing. Companies including CARsgen Therapeutics, JW Therapeutics, Nanjing Legend Biotech, and Gracell Biotechnologies (acquired by AstraZeneca in 2023) have built end-to-end CAR-T manufacturing within China. This covers viral vector production, cell processing, quality control, and cold-chain delivery. It reduces dependence on imported components and keeps per-patient manufacturing costs lower than in countries where production is contracted overseas.
Published clinical data. Chinese CAR-T programs have published patient outcome data in peer-reviewed international journals including Nature Medicine, Journal of Clinical Oncology, and Blood. This allows external review of their results by the global oncology community.
What CAR-T Costs in China
Product | Indication | Approximate Cost (USD) |
Relma-cel | Large B-cell Lymphoma | $50,000–$80,000 |
Yescarta (Fosun Kite) | B-cell Lymphoma | $70,000–$100,000 |
Equecabtagene autoleucel | Multiple Myeloma | $60,000–$90,000 |
Clinical trial enrollment | Varies by trial | Often partially subsidized |
The figures above cover the CAR-T cell product. Pre-conditioning chemotherapy, hospital stay, and post-infusion monitoring typically add $15,000–$30,000.
For direct comparison: the drug cost alone in the United States for a clinically equivalent product is $370,000–$475,000. A patient from Indonesia or Vietnam can travel to Shanghai or Guangzhou, complete a full course of CAR-T therapy, remain for the required 8–12 weeks of post-infusion monitoring, and return home — with total out-of-pocket costs that remain well below the US drug price alone.
Which Hospitals in China Offer CAR-T
The following hospitals have documented CAR-T programs with published data:
Tongji Hospital, Wuhan — affiliated with Huazhong University of Science and Technology; among the highest CAR-T case volumes in China
Ruijin Hospital, Shanghai — affiliated with Shanghai Jiao Tong University School of Medicine; strong hematology department with published CAR-T data
Peking University People's Hospital, Beijing — nationally recognized for blood cancer treatment
West China Hospital, Chengdu — consistently rated among China's top five hospitals by clinical output measures
Sun Yat-sen University Cancer Center, Guangzhou — Guangzhou has direct flight connections from Jakarta, Kuala Lumpur, Ho Chi Minh City, Bangkok, and Manila, making this center logistically practical for Southeast Asian patients
For patients navigating hospital selection, medical record translation, visa categories, and ongoing communication with treating physicians, coordination services reduce the risk of logistical failures and delays. ChinaCureLink connects Southeast Asian patients with verified oncology centers in China, manages documentation transfer between local and overseas physicians, and provides translation support across Bahasa Indonesia, Vietnamese, Thai, Filipino, and Mandarin.
3. 🇩🇪 Germany
Germany has approved the full EMA CAR-T product list — Kymriah, Yescarta, Carvykti, Breyanzi, and Tecartus (brexucabtagene autoleucel for mantle cell leukemia). Established programs operate at University Hospital Frankfurt, LMU Munich, and Charité Berlin. Patient outcomes are tracked through national cancer registries.
Approximate total cost for an international patient: €350,000–€550,000 ($375,000–$590,000 USD)
EU residents with statutory health insurance may receive coverage. International patients pay out-of-pocket at private rates. Clinical consultations are conducted primarily in German, though major academic centers maintain English-speaking medical teams. The combination of distance from Southeast Asia and high cost makes Germany a practical option only for patients with a specific clinical reason to choose it — such as eligibility for a trial not available elsewhere.
4. 🇮🇳 India
India approved its first domestically developed CAR-T product — NexCAR19, produced by ImmunoACT in collaboration with IIT Bombay and Tata Memorial Hospital — in 2023. This made India the second country after China to have a homegrown CAR-T product receive national regulatory approval.
NexCAR19 targets CD19, making it applicable to relapsed or refractory B-cell ALL and B-cell lymphoma. The clinical trial data showed response rates consistent with international benchmarks for CD19 CAR-T products. The product uses a humanized CAR construct, which the trial data suggested may produce a lower rate of high-grade cytokine release syndrome compared to some earlier products — though direct comparative data against other approved products is not yet available.
Approximate cost: INR 40–50 lakh ($48,000–$60,000 USD) — the lowest price point of any nationally approved CAR-T product globally as of 2026.
Tata Memorial Hospital in Mumbai, where NexCAR19 was developed, is one of Asia's highest-volume cancer hospitals and has an established process for international patients.
Points to consider:
Only one approved product, covering only CD19-positive cancers. Patients with multiple myeloma (which requires BCMA-targeting) or other indications have no approved option domestically.
Infrastructure for intensive post-infusion ICU-level monitoring is strong at Tata Memorial but variable at other centers.
No approved solid tumor CAR-T program currently exists in India.
For patients with CD19-positive relapsed or refractory B-cell ALL or large B-cell lymphoma, India's program is worth evaluating given the cost. For other diagnoses, China has broader product coverage.
5. 🇯🇵 Japan
Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved several CAR-T products, and programs operate at the National Cancer Center Japan in Tokyo and affiliated university hospitals. Post-infusion care is thorough and systematically organized.
Approximate cost for international patients: $300,000–$400,000 USD total.
Japan's healthcare system is built around its national insurance program. International patients pay private rates without access to subsidized pricing. Clinical consultations and all documentation are in Japanese, and translation support for Southeast Asian languages is limited outside of a small number of hospital international patient departments.
Japan's costs fall between China and the United States without offering a clear clinical or logistical advantage over China for Southeast Asian patients seeking CAR-T specifically.
Country Comparison (2026)
Country | Nationally Approved Products | Approx. Total Cost (USD) | Solid Tumor Trials | Access Notes for SEA Patients |
🇺🇸 USA | 7 | $500,000–$800,000 | Active | Visa difficulty, high cost, 10–14 week stay required |
🇨🇳 China | 3 approved + largest active trial pipeline | $65,000–$130,000 | Most active globally | Closest geographically, lowest cost among high-volume programs |
🇩🇪 Germany | 5 (EMA-approved) | $375,000–$590,000 | Active | High cost, language barrier, long distance |
🇮🇳 India | 1 domestic (CD19 only) | $48,000–$65,000 | Limited | Low cost, narrow product range, strong for B-ALL and DLBCL |
🇯🇵 Japan | 4 | $300,000–$400,000 | Active | High cost, language barrier, limited SEA patient infrastructure |
What Southeast Asian Patients Need to Know Before Traveling for CAR-T Treatment
Eligibility Is Not Automatic
CAR-T therapy is not appropriate for all patients, even those with a qualifying diagnosis. Most approved programs require:
Relapsed or refractory disease: The patient has already received two or more prior lines of treatment without achieving durable remission.
Adequate physical condition: The patient must be well enough to tolerate lymphodepletion chemotherapy, which is administered before the CAR-T infusion.
Organ function: Liver, kidney, and cardiac function must fall within acceptable ranges.
Confirmed target antigen expression: The patient's cancer cells must express the specific antigen the CAR-T product targets — CD19 for B-cell cancers, BCMA for multiple myeloma. This must be confirmed on pathology.
Before contacting any overseas hospital, ask your treating oncologist to prepare a written clinical summary: your diagnosis, staging, full treatment history, pathology reports with antigen testing, and current functional status. Most international centers require this documentation to conduct an eligibility assessment.
How Long Does Treatment Take?
Plan for a minimum of 8–12 weeks at the treatment destination. Patients who return home before the monitoring period ends face real risk.
Phase | Typical Duration |
Initial consultation and eligibility review | 1–2 weeks |
Leukapheresis (T-cell collection) | 1 day + 2–3 days recovery |
Cell manufacturing and expansion | 3–4 weeks |
Pre-conditioning chemotherapy | 1 week |
CAR-T infusion | 1 day |
Inpatient monitoring (CRS / ICANS period) | 2–4 weeks |
Outpatient follow-up at treating center | 4–6 weeks |
Most programs require patients to remain within a defined distance of the hospital during the outpatient monitoring phase. Arrange accommodation for a companion if possible — having a family member present during the monitoring period is practically and psychologically important.
Side Effects That Require On-Site Management
CAR-T carries serious potential side effects that require immediate clinical response and cannot be managed remotely. Understanding these is part of making an informed decision.
Cytokine Release Syndrome (CRS): The immune response triggered by activated CAR-T cells can cause a systemic inflammatory reaction. Mild cases resemble severe influenza. Serious cases involve low blood pressure, reduced oxygen saturation, and organ stress. The standard treatment is tocilizumab (an IL-6 receptor blocker) and corticosteroids. Most cases occur within the first week after infusion.
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): Some patients develop neurological effects including confusion, difficulty speaking, tremor, or — in serious cases — seizures and raised intracranial pressure. This requires neurological monitoring and, where severe, intensive care support.
Prolonged low blood counts: Lymphodepletion chemotherapy and CAR-T both suppress the bone marrow, sometimes for weeks to months. Blood and platelet transfusions and strict infection precautions are typically required during this period.
Infection risk: Suppressed immunity during and after treatment leaves patients vulnerable to bacterial, viral, and fungal infections.
These side effects are clinically manageable at experienced centers with dedicated CAR-T teams and on-site capacity for tocilizumab administration and ICU-level support. When evaluating a hospital, ask specifically how many CAR-T infusions they have performed and what their CRS grading and treatment protocol looks like.
Practical Steps for Patients From Southeast Asia
Language, medical record translation, visa documentation, and coordination between your overseas treating hospital and your home oncologist are real, manageable obstacles — but they require planning.
For patients from Indonesia, Malaysia, Vietnam, Thailand, and the Philippines seeking treatment in China, ChinaCureLink (a Medebound HEALTH company) provides patient coordination across the full process: matching clinical profiles to appropriate hospitals, translating and transferring medical records, and supporting communication between patients, families, and treating physicians throughout the treatment stay.
About China CureLink(Medebound HEALTH): Founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific. Contact us below for free medical record review.
Frequently Asked Questions
Can CAR-T therapy produce a complete remission?
Yes, in some patients. The strongest evidence is in pediatric and young adult B-cell ALL, where complete remission rates in relapsed or refractory disease exceed 70–80% in published trial data. Long-term follow-up data shows a subset of these patients remaining in remission at five years without further treatment. For diffuse large B-cell lymphoma and multiple myeloma, response rates are clinically meaningful but relapse occurs in a significant proportion of patients. CAR-T is not a guaranteed cure; it offers a meaningful probability of deep, potentially durable response in patients who have run out of standard options.
Can I return home after the infusion?
Not immediately. Most programs require patients to remain near the treating hospital for at least 6–8 weeks post-infusion because of the CRS and ICANS risk window. After this period, and after the treating physician has cleared the patient for travel, most patients can return home. Share your travel plans with the treating team and ensure your home oncologist has a copy of your treatment records before you leave.
Are clinical trials worth considering?
For some patients, yes. Trials of next-generation CAR-T products — dual-target constructs, allogeneic (donor-derived, not patient-specific) cells, and products targeting new antigens in solid tumors — are enrolling internationally eligible patients at several Chinese centers. Trial costs are often partially or fully covered. Ask specifically about trial availability at your initial consultation, and review the eligibility criteria carefully before traveling.
How do I verify that a hospital's CAR-T program is credible?
Request the hospital's accreditation documentation, the treating oncologist's credentials and reported CAR-T case volume, published clinical outcome data, the specific NMPA approval status of the product being used, and a detailed description of their CRS and ICANS management protocols. Any program that cannot provide these should be treated with caution.
About China Curelink
China Curelink helps patients across Southeast Asia — including Indonesia, Malaysia, the Philippines, Vietnam, and Thailand — access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top 5 cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team that understands both the medical and cultural needs of Southeast Asian patients.
China Curelink is proudly affiliated with Medebound HEALTH— an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia Pacific, Medebound HEALTH brings the same standard of expert care coordination to every patient we serve.
This article is for informational purposes only and does not constitute medical advice. All treatment decisions should be made in consultation with a qualified oncologist who has reviewed your complete medical history and current diagnostic information.
Comments